

OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person * <u>Geist William</u> _____ (Last) (First) (Middle) <u>614 MCKINLEY PLACE NE</u> _____ (Street) <u>MINNEAPOLIS MN 55413</u> _____ (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>BIO-TECHNE Corp [ TECH ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>PRESIDENT, PROTEIN SCIENCES</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>11/01/2024</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price				
Common Stock	11/01/2024		M		9,912	A	\$0	14,351	D		
Common Stock	11/01/2024		F		3,270	D	\$75.31	11,081	D		

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	(1)							(2)	(2)	Common Stock	3,320		3,320	D	
Stock Options (Right to Buy)	\$100.39							(3)	02/01/2029	Common Stock	15,912		15,912	D	
Performance Restricted Stock Units	(1)							(4)	(4)	Common Stock	7,140		7,140	D	
Performance Stock Options (Right to Buy)	\$94.52							(4)	(4)	Common Stock	22,200		22,200	D	
Stock Options (Right to Buy)	\$94.52							(5)	08/15/2029	Common Stock	29,600		29,600	D	
Performance Restricted Stock Units	(1)							(6)	(6)	Common Stock	9,074		9,074	D	
Performance Stock Options (Right to Buy)	\$84.61							(6)	(6)	Common Stock	24,424		24,424	D	
Stock Options (Right to Buy)	\$84.61							(7)	08/15/2030	Common Stock	30,059		30,059	D	
Restricted Stock Units	(1)	11/01/2024		M		9,912		(8)	(8)	Common Stock	9,912	\$0	9,911	D	
Performance Restricted Stock Units	(1)							(9)	(9)	Common Stock	15,738		15,738	D	
Restricted Stock Units	(1)							(10)	(10)	Common Stock	7,869		7,869	D	
Stock Options (Right to Buy)	\$74.91							(11)	08/15/2034	Common Stock	21,204		21,204	D	

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
2. 3,320 restricted stock units vest on 2/1/2025.
3. Options to purchase 3,980 shares vest on each of 2/1/2023 and 2/1/2025, and options to purchase 3,976 shares vest on each of 2/1/2024 and 2/1/2026.
4. Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
5. Options to purchase 7,400 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.
6. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
7. Options to purchase 7,515 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2027, and 7,514 shares vest on 8/15/2026.
8. 9,911 restricted stock units vest on 11/1/2025.
9. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
10. 2,623 restricted stock units vest on each of 8/15/2025, 8/15/2026 and 8/15/2027.
11. Options to purchase 5,301 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.

[/s/ Andrew Nick as Attorney-in-Fact for William Geist pursuant to 11/05/2024 Power of Attorney previously filed](#)

\*\* Signature of Reporting Person                      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**